Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2.
Authors
Richard S. Finn
David Geffen School of Medicine at UCLA, Los Angeles, CA
Richard S. Finn , Thomas Yau , Chih-Hung Hsu , Enrico N. De Toni , Lipika Goyal , Peter R. Galle , Shukui Qin , Sujata Rao , Fangfang Sun , Chunxiao Wang , Ryan C Widau , Andrew X. Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02435433
DOI
10.1200/JCO.2022.40.4_suppl.423
Abstract #
423
Poster Bd #
B9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
First Author: Julien Edeline
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
First Author: Julien Edeline
Poster
2021 ASCO Annual Meeting
Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.
First Author: William Joseph Chapin
Poster
2021 ASCO Annual Meeting
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
First Author: Philipp K. Haber